PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24465768-7	2014	Monotherapy with olmesartan and its combination with sorafenib resulted in a significant reduction in microvessel density and serum levels of VEGF and IGF-I, as well as their intratumoral receptors.	olmesartan	17-27	vascular endothelial growth factor A	Mus musculus	142-146	
24465768-9	2014	In conclusion, olmesartan reduced the levels of the angiogenesis markers IGF-I and VEGF and down-regulated the intratumoral expression of their receptors in a dose-dependent manner, and these effects were dependent on the angiotensin (1-7) receptor.	olmesartan	15-25	vascular endothelial growth factor A	Mus musculus	83-87